

Francesco Cosentino

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5730282/publications.pdf>

Version: 2024-02-01

214
papers

25,885
citations

19657

61
h-index

6836

155
g-index

223
all docs

223
docs citations

223
times ranked

25367
citing authors

#	ARTICLE	IF	CITATIONS
1	Guideline Development for Medical Device Technology: Issues for Consideration. Journal of Diabetes Science and Technology, 2023, 17, 1698-1710.	2.2	2
2	Protective effects of SGLT-2 inhibitors across the cardiorenal continuum: two faces of the same coin. European Journal of Preventive Cardiology, 2022, 29, 1352-1360.	1.8	26
3	2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. European Journal of Preventive Cardiology, 2022, 29, 5-115.	1.8	220
4	Vascular repair and regeneration in cardiometabolic diseases. European Heart Journal, 2022, 43, 450-459.	2.2	8
5	The year in cardiovascular medicine 2021: diabetes and metabolic disorders. European Heart Journal, 2022, 43, 263-270.	2.2	7
6	The differential effects of ertugliflozin on glucosuria and natriuresis biomarkers: Prespecified analyses from <scp>VERTIS CV</scp>. Diabetes, Obesity and Metabolism, 2022, 24, 1114-1122.	4.4	5
7	Cardiorenal outcomes with ertugliflozin assessed according to baseline glucose-lowering agent: An analysis from <scp>VERTIS CV</scp>. Diabetes, Obesity and Metabolism, 2022, , .	4.4	5
8	Effect of Oral Semaglutide on Cardiovascular Parameters and Their Mechanisms in Patients with Type 2 Diabetes: Rationale and Design of the Semaglutide Anti-Atherosclerotic Mechanisms of Action Study (SAMAS). Diabetes Therapy, 2022, 13, 795-810.	2.5	9
9	Ertugliflozin, renoprotection and potential confounding by muscle wasting. Reply to Groothof D, Post A, Gans ROB et al [letter]. Diabetologia, 2022, 65, 908-911.	6.3	0
10	Eligibility for Dapagliflozin and Empagliflozin in a Real-world Heart Failure Population. Journal of Cardiac Failure, 2022, 28, 1050-1062.	1.7	19
11	Heart and Kidney Outcomes With Ertugliflozin in People with Non-albuminuric Diabetic Kidney Disease: A post hoc Analysis from the Randomized VERTIS CV Trial. Kidney International Reports, 2022, 7, 1782-1792.	0.8	4
12	Mediators of ertugliflozin effects on heart failure and kidney outcomes among patients with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism, 2022, 24, 1829-1839.	4.4	23
13	Emerging role for SGLT2 inhibitors in mitigating the risk of hyperkalaemia in heart failure. European Heart Journal, 2022, 43, 2994-2996.	2.2	6
14	Non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease. European Heart Journal, 2022, 43, 2931-2945.	2.2	14
15	Initial eGFR Changes with Ertugliflozin and Associations with Clinical Parameters: Analyses from the VERTIS CV Trial. American Journal of Nephrology, 2022, 53, 516-525.	3.1	7
16	Endothelial function in cardiovascular medicine: a consensus paper of the European Society of Cardiology Working Groups on Atherosclerosis and Vascular Biology, Aorta and Peripheral Vascular Diseases, Coronary Pathophysiology and Microcirculation, and Thrombosis. Cardiovascular Research, 2021, 117, 29-42.	3.8	164
17	Profile and treatment of chronic coronary syndromes in European Society of Cardiology member countries: The ESC EORP CICD-LT registry. European Journal of Preventive Cardiology, 2021, 28, 432-445.	1.8	11
18	Guideline recommendations and the positioning of newer drugs in type 2 diabetes care. Lancet Diabetes and Endocrinology, the, 2021, 9, 46-52.	11.4	103

#	ARTICLE	IF	CITATIONS
19	Investigating the possible impact of peritoneal tumor exposure amongst women with early stage cervical cancer treated with minimally invasive approach. <i>European Journal of Surgical Oncology</i> , 2021, 47, 1090-1097.	1.0	15
20	Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes. <i>JAMA Cardiology</i> , 2021, 6, 148.	6.1	625
21	Gradient of Risk and Associations With Cardiovascular Efficacy of Ertugliflozin by Measures of Kidney Function. <i>Circulation</i> , 2021, 143, 602-605.	1.6	24
22	Role of minimally invasive surgery versus open approach in patients with early-stage uterine carcinosarcomas: a retrospective multicentric study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 845-852.	2.5	7
23	The ESC-EORP Chronic Ischaemic Cardiovascular Disease Long Term (CICD LT) registry. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2021, 7, 28-33.	4.0	2
24	The year in cardiovascular medicine 2020: epidemiology and prevention. <i>European Heart Journal</i> , 2021, 42, 813-821.	2.2	18
25	Report from the CVOT Summit 2020: new cardiovascular and renal outcomes. <i>Cardiovascular Diabetology</i> , 2021, 20, 75.	6.8	9
26	Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial. <i>Diabetologia</i> , 2021, 64, 1256-1267.	6.3	103
27	Use of sodium-glucose cotransporter 2 inhibitors in patients with heart failure and type 2 diabetes mellitus: data from the Swedish Heart Failure Registry. <i>European Journal of Heart Failure</i> , 2021, 23, 1012-1022.	7.1	33
28	Positioning newer drugs in the management of type 2 diabetes. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 139-140.	11.4	3
29	Kidney outcomes using a sustained $\geq 40\%$ decline in eGFR: A meta-analysis of SGLT2 inhibitor trials. <i>Clinical Cardiology</i> , 2021, 44, 1139-1143.	1.8	20
30	Ertugliflozin and Slope of Chronic eGFR. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 1345-1354.	4.5	26
31	Cardiac, renal, and metabolic effects of sodium-glucose cotransporter 2 inhibitors: a position paper from the European Society of Cardiology ad hoc task force on sodium-glucose cotransporter 2 inhibitors. <i>European Journal of Heart Failure</i> , 2021, 23, 1260-1275.	7.1	36
32	Towards living guidelines on cardiorenal outcomes in diabetes: A pilot project of the Taskforce of the Guideline Workshop 2020. <i>Diabetes Research and Clinical Practice</i> , 2021, 177, 108870.	2.8	4
33	2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. <i>European Heart Journal</i> , 2021, 42, 3227-3337.	2.2	2,517
34	A Multicentric Randomized Trial to Evaluate the ROle of Uterine MANipulator on Laparoscopic/Robotic HYsterectomy for the Treatment of Early-Stage Endometrial Cancer: The ROMANHY Trial. <i>Frontiers in Oncology</i> , 2021, 11, 720894.	2.8	11
35	Sodium-Glucose Cotransporter 2 Inhibitors, All-Cause Mortality, and Cardiovascular Outcomes in Adults with Type 2 Diabetes: A Bayesian Meta-Analysis and Meta-Regression. <i>Journal of the American Heart Association</i> , 2021, 10, e019918.	3.7	8
36	Glucose-lowering therapy in patients undergoing percutaneous coronary intervention. <i>EuroIntervention</i> , 2021, 17, e618-e630.	3.2	3

#	ARTICLE	IF	CITATIONS
37	SGLT2i: new perspectives in diabetes and kidney disease. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, e4-e4.	3.0	0
38	Glycemic efficacy and safety of the SGLT2 inhibitor ertugliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease: an analysis from the VERTIS CV randomized trial. <i>BMJ Open Diabetes Research and Care</i> , 2021, 9, e002484.	2.8	14
39	Heart failure in type 2 diabetes: current perspectives on screening, diagnosis and management. <i>Cardiovascular Diabetology</i> , 2021, 20, 218.	6.8	38
40	Promoting a Syndemic Approach for Cardiometabolic Disease Management During COVID-19: The CAPISCO International Expert Panel. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 787761.	2.4	38
41	High-intensity interval training modulates retinal microvascular phenotype and DNA methylation of p66Shc gene: a randomized controlled trial (EXAMIN AGE). <i>European Heart Journal</i> , 2020, 41, 1514-1519.	2.2	38
42	Physical activity may drive healthy microvascular ageing via downregulation of p66 ^{Shc} . <i>European Journal of Preventive Cardiology</i> , 2020, 27, 168-176.	1.8	18
43	2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. <i>European Heart Journal</i> , 2020, 41, 255-323.	2.2	2,811
44	Primary versus secondary cardiorenal prevention in type 2 diabetes: Which newer anti-hyperglycaemic drug matters?. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 149-157.	4.4	21
45	The year in cardiology: cardiovascular prevention. <i>European Heart Journal</i> , 2020, 41, 1157-1163.	2.2	13
46	How to Select Early-Stage Cervical Cancer Patients Still Suitable for Laparoscopic Radical Hysterectomy: a Propensity-Matched Study. <i>Annals of Surgical Oncology</i> , 2020, 27, 1947-1955.	1.5	63
47	European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure. <i>European Journal of Heart Failure</i> , 2020, 22, 196-213.	7.1	131
48	Compelling evidence for SGLT2 inhibitors and GLP-1 receptor agonists as first-line therapy in patients with diabetes at very high/high cardiovascular risk. <i>European Heart Journal</i> , 2020, 41, 329-330.	2.2	10
49	Long-term evaluation of quality of life and gastrointestinal well-being after segmental colo-rectal resection for deep infiltrating endometriosis (ENDO-RESECT QoL). <i>Archives of Gynecology and Obstetrics</i> , 2020, 301, 217-228.	1.7	20
50	Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease. <i>Circulation</i> , 2020, 142, 2205-2215.	1.6	156
51	<sc>Heart Failure Association</sc> of the <sc>European Society of Cardiology</sc> update on sodium-glucose co-transporter 2 inhibitors in heart failure. <i>European Journal of Heart Failure</i> , 2020, 22, 1984-1986.	7.1	66
52	Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850). <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1657-1664.	2.5	220
53	CardioScape-II: the need to map cardiovascular funding patterns in Europe. <i>Cardiovascular Research</i> , 2020, 116, 879-881.	3.8	0
54	Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2020, 383, 1425-1435.	27.0	927

#	ARTICLE	IF	CITATIONS
55	Non-Insulin antihyperglycaemic drugs and heart failure: an overview of current evidence from randomized controlled trials. <i>ESC Heart Failure</i> , 2020, 7, 3438-3451.	3.1	13
56	The interaction between dapagliflozin and blood pressure in heart failure: new evidence dissipating concerns. <i>European Heart Journal</i> , 2020, 41, 3419-3420.	2.2	6
57	Hyperglycemia Induces Myocardial Dysfunction via Epigenetic Regulation of JunD. <i>Circulation Research</i> , 2020, 127, 1261-1273.	4.5	38
58	Comorbidities and cause-specific outcomes in heart failure across the ejection fraction spectrum: A blueprint for clinical trial design. <i>International Journal of Cardiology</i> , 2020, 313, 76-82.	1.7	30
59	Diabetes and coronary artery disease: not just a risk factor. <i>Heart</i> , 2020, 106, 1357-1364.	2.9	13
60	Should the Number of Metastatic Pelvic Lymph Nodes Be Integrated into the 2018 Figo Staging Classification of Early Stage Cervical Cancer?. <i>Cancers</i> , 2020, 12, 1552.	3.7	24
61	High awareness of diabetes as a key cardiovascular risk factor among healthcare professionals but suboptimal treatment: Results from a survey of the European Association of Preventive Cardiology. <i>European Journal of Preventive Cardiology</i> , 2020, , 2047487320911845.	1.8	4
62	Laparoscopic treatment of ovarian granulosa cells tumor developed in the pelvic anterior preperitoneal space 20 years after laparotomic salpingo-oophorectomy: case report and review of literature. <i>Gynecological Endocrinology</i> , 2020, 36, 926-928.	1.7	4
63	Sodium-glucose co-transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2020, 22, 1495-1503.	7.1	100
64	Rare Case of Endoscopic Treatment for Bevacizumab-Related Gastric Perforation in a Patient with Ovarian Cancer. <i>Chemotherapy</i> , 2020, 65, 54-57.	1.6	2
65	Feasibility and safety of two different surgical routes for the eradication of recto-vaginal endometriosis with vaginal mucosa infiltration (Endo-Vag study). <i>Acta Obstetricia Et Gynecologica Scandinavica</i> , 2020, 99, 1050-1056.	2.8	9
66	Prevention and treatment of venous thromboembolism. <i>European Heart Journal Supplements</i> , 2020, 22, C1-C1.	0.1	0
67	Laparotomy approach to sentinel lymph node detection in ovarian cancer using a near-infrared fluorescent system camera with indocyanine green dye. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 712-713.	2.5	5
68	Extreme complications related to bevacizumab use in the treatment of ovarian cancer: a case series from a III level referral centre and review of the literature. <i>Annals of Translational Medicine</i> , 2020, 8, 1687-1687.	1.7	6
69	Highlights from the 2019 International Aspirin Foundation Scientific Conference, Rome, 28 June 2019: benefits and risks of antithrombotic therapy for cardiovascular disease prevention. <i>Ecancermedicalscience</i> , 2020, 14, 998.	1.1	4
70	The year in cardiology: cardiovascular prevention /The year in cardiology 2019. <i>Revista Romana De Cardiologie</i> , 2020, 30, 20-29.	0.1	0
71	The 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. <i>European Heart Journal</i> , 2019, 40, 3215-3217.	2.2	132
72	Arterial-enteric fistula after pelvic lymphadenectomy in secondary cytoreductive surgery for recurrent ovarian cancer. <i>Journal of Obstetrics and Gynaecology</i> , 2019, 39, 1049-1056.	0.9	9

#	ARTICLE	IF	CITATIONS
73	The environment, epigenetic landscape and cardiovascular risk. <i>Cardiovascular Research</i> , 2019, 115, e147-e150.	3.8	2
74	The combination of coronary artery disease and type 2 diabetes: a therapeutic challenge. <i>European Heart Journal Supplements</i> , 2019, 21, C37-C39.	0.1	0
75	Exercise-induced improvement of microvascular phenotype and reprogramming of p66Shc DNA methylation. <i>European Heart Journal</i> , 2019, 40, 3948-3949.	2.2	5
76	Cardio-diabetology: The new "sweetheart"™ in cardiovascular prevention. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 5-6.	1.8	2
77	Addressing cardiovascular risk in type 2 diabetes mellitus: a report from the European Society of Cardiology Cardiovascular Roundtable. <i>European Heart Journal</i> , 2019, 40, 2907-2919.	2.2	32
78	The year in cardiology 2018: prevention. <i>European Heart Journal</i> , 2019, 40, 336-344.	2.2	26
79	Sirtuin 1/soluble guanylyl cyclase: a nitric oxide-independent pathway to rescue ageing-induced vascular dysfunction. <i>Cardiovascular Research</i> , 2019, 115, 485-487.	3.8	6
80	Obesity-induced impairment of pluripotent stem cells: novel insights into vascular repair strategies. <i>European Heart Journal</i> , 2019, 40, e11-e13.	2.2	1
81	Interplay among H3K9-editing enzymes SUV39H1, JMJD2C and SRC-1 drives p66Shc transcription and vascular oxidative stress in obesity. <i>European Heart Journal</i> , 2019, 40, 383-391.	2.2	45
82	Robotic versus laparoscopic radical hysterectomy in early cervical cancer: A case matched control study. <i>European Journal of Surgical Oncology</i> , 2018, 44, 754-759.	1.0	55
83	Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2018, 20, 853-872.	7.1	434
84	Glucose-lowering treatment in cardiovascular and peripheral artery disease. <i>Current Opinion in Pharmacology</i> , 2018, 39, 86-98.	3.5	6
85	The chronic ischaemic cardiovascular disease ESC Pilot Registry: Results of the six-month follow-up. <i>European Journal of Preventive Cardiology</i> , 2018, 25, 377-387.	1.8	12
86	Utilizing NT-proBNP for Eligibility and Enrichment in Trials in HFpEF, HFmrEF, and HFrEF. <i>JACC: Heart Failure</i> , 2018, 6, 246-256.	4.1	47
87	Diabetes and ischaemic stroke: a deadly association. <i>European Heart Journal</i> , 2018, 39, 2387-2389.	2.2	10
88	The year in cardiology 2017: prevention. <i>European Heart Journal</i> , 2018, 39, 345-353.	2.2	3
89	Near-Infrared Imaging with Indocyanine Green for Detection of Endometriosis Lesions (Gre-Endo) Tj ETQq1 1 0.784314 rgBT /Overlock 1 0.6 44	0.6	44
90	Predictors of mortality in hospital survivors with type 2 diabetes mellitus and acute coronary syndromes. <i>Diabetes and Vascular Disease Research</i> , 2018, 15, 14-23.	2.0	18

#	ARTICLE	IF	CITATIONS
91	Epigenetics and Immunometabolism in Diabetes and Aging. <i>Antioxidants and Redox Signaling</i> , 2018, 29, 257-274.	5.4	63
92	Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. <i>European Heart Journal</i> , 2018, 39, 4243-4254.	2.2	171
93	Design and baseline characteristics of the eValuation of ERTugliflozin efficacy and Safety CardioVascular outcomes trial (VERTIS-CV). <i>American Heart Journal</i> , 2018, 206, 11-23.	2.7	171
94	GLP-1 receptor agonists and reduction of cardiometabolic risk: Potential underlying mechanisms. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2018, 1864, 2814-2821.	3.8	104
95	Neo-adjuvant platinum-based chemotherapy followed by chemoradiation and radical surgery in locally advanced cervical cancer (Lacc) patients: A phase II study. <i>European Journal of Surgical Oncology</i> , 2018, 44, 1062-1068.	1.0	28
96	Hyperglycaemia-induced epigenetic changes drive persistent cardiac dysfunction via the adaptor p66Shc. <i>International Journal of Cardiology</i> , 2018, 268, 179-186.	1.7	47
97	Laparoscopic Management of Abdominal Pregnancy. <i>Journal of Minimally Invasive Gynecology</i> , 2017, 24, 724-725.	0.6	20
98	Diabetes: Prevalence, prognosis and management of a potent cardiovascular risk factor. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 52-60.	1.8	41
99	Post-Discharge Worsening Renal Function in Patients with Type 2 Diabetes and Recent Acute Coronary Syndrome. <i>American Journal of Medicine</i> , 2017, 130, 1068-1075.	1.5	4
100	Impact of Glycemic Variability on Chromatin Remodeling, Oxidative Stress, and Endothelial Dysfunction in Patients With Type 2 Diabetes and With Target HbA1c Levels. <i>Diabetes</i> , 2017, 66, 2472-2482.	0.6	139
101	Ageing, metabolism and cardiovascular disease. <i>Journal of Physiology</i> , 2016, 594, 2061-2073.	2.9	311
102	Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia. <i>European Heart Journal Supplements</i> , 2016, 18, C2-C12.	0.1	71
103	Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome. <i>European Journal of Cancer</i> , 2016, 59, 22-33.	2.8	297
104	Pin1 inhibitor Juglone prevents diabetic vascular dysfunction. <i>International Journal of Cardiology</i> , 2016, 203, 702-707.	1.7	39
105	Reprogramming ageing and longevity genes restores paracrine angiogenic properties of early outgrowth cells. <i>European Heart Journal</i> , 2016, 37, 1733-1737.	2.2	27
106	MicroRNA profiling unveils hyperglycaemic memory in the diabetic heart. <i>European Heart Journal</i> , 2016, 37, 572-576.	2.2	136
107	Minimally invasive interval debulking surgery in ovarian neoplasm (MISSION trial): a feasibility study. <i>American Journal of Obstetrics and Gynecology</i> , 2016, 214, 503.e1-503.e6.	1.3	66
108	Telelap ALF-X vs Standard Laparoscopy for the Treatment of Early-Stage Endometrial Cancer: A Single-Institution Retrospective Cohort Study. <i>Journal of Minimally Invasive Gynecology</i> , 2016, 23, 378-383.	0.6	44

#	ARTICLE	IF	CITATIONS
109	EURObservational Research Programme: the Chronic Ischaemic Cardiovascular Disease Registry: Pilot phase (CICD-PILOT). <i>European Heart Journal</i> , 2016, 37, 152-160.	2.2	29
110	Comparative associations between angiotensin converting enzyme inhibitors, angiotensin receptor blockers and their combination, and outcomes in patients with heart failure and reduced ejection fraction. <i>International Journal of Cardiology</i> , 2015, 199, 415-423.	1.7	7
111	Adverse Epigenetic Signatures by Histone Methyltransferase Set7 Contribute to Vascular Dysfunction in Patients With Type 2 Diabetes Mellitus. <i>Circulation: Cardiovascular Genetics</i> , 2015, 8, 150-158.	5.1	141
112	Hyperglycemia. , 2015, , 85-100.		0
113	Diabetes and Cardiovascular Disease. , 2015, , 13-21.		0
114	Molecular pathways of arterial aging. <i>Clinical Science</i> , 2015, 128, 69-79.	4.3	42
115	The role of vascular biomarkers for primary and secondary prevention. A position paper from the European Society of Cardiology Working Group on peripheral circulation. <i>Atherosclerosis</i> , 2015, 241, 507-532.	0.8	587
116	Epidemiology, Definition, and Diagnosis of Diabetes Mellitus. , 2015, , 3-12.		2
117	A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrateâ€“statin combination therapy. <i>Atherosclerosis Supplements</i> , 2015, 19, 1-12.	1.2	66
118	Targeting prolyl-isomerase Pin1 prevents mitochondrial oxidative stress and vascular dysfunction: insights in patients with diabetes. <i>European Heart Journal</i> , 2015, 36, 817-828.	2.2	75
119	Mechanisms of Diabetic Atherosclerosis. , 2015, , 23-33.		1
120	Targeting Chromatin Remodeling to Prevent Cardiovascular Disease in Diabetes. <i>Current Pharmaceutical Biotechnology</i> , 2015, 16, 531-543.	1.6	30
121	Hyperglycemia: a bad signature on the vascular system. <i>Cardiovascular Diagnosis and Therapy</i> , 2015, 5, 403-6.	1.7	17
122	Role of oxidative stress in endothelial insulin resistance. <i>World Journal of Diabetes</i> , 2015, 6, 326.	3.5	51
123	Risk Stratification. , 2015, , 69-83.		0
124	Ischemic Stroke. , 2015, , 189-202.		0
125	Environment, Epigenetic Changes, and Cardiovascular Damage. , 2015, , 35-47.		0
126	Antiplatelet Therapy. , 2015, , 133-144.		0

#	ARTICLE	IF	CITATIONS
127	Arterial Hypertension. , 2015, , 115-131.		0
128	ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD – Summary. Diabetes and Vascular Disease Research, 2014, 11, 133-173.	2.0	173
129	Non-coronary atherosclerosis. European Heart Journal, 2014, 35, 1112-1119.	2.2	136
130	Guía de práctica clínica de la ESC sobre diabetes, prediabetes y enfermedad cardiovascular, en colaboración con la European Association for the Study of Diabetes. Revista Espanola De Cardiologia, 2014, 67, 136.e1-136.e56.	1.2	15
131	Insulin Resistance, Diabetes, and Cardiovascular Risk. Current Atherosclerosis Reports, 2014, 16, 419.	4.8	129
132	Advanced glycation endproducts and plaque instability: a link beyond diabetes. European Heart Journal, 2014, 35, 1095-1097.	2.2	8
133	p66Shc-induced redox changes drive endothelial insulin resistance. Atherosclerosis, 2014, 236, 426-429.	0.8	31
134	Molecular mechanisms of vascular dysfunction and cardiovascular biomarkers in type 2 diabetes. Cardiovascular Diagnosis and Therapy, 2014, 4, 324-32.	1.7	30
135	Epigenetic signatures and vascular risk in type 2 diabetes: A clinical perspective. Atherosclerosis, 2013, 230, 191-197.	0.8	62
136	Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II. European Heart Journal, 2013, 34, 2444-2452.	2.2	282
137	ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. European Heart Journal, 2013, 34, 3035-3087.	2.2	1,758
138	Mechanisms of Cardiovascular Aging. Current Translational Geriatrics and Experimental Gerontology Reports, 2013, 2, 275-283.	0.7	1
139	Deletion of the Activated Protein-1 Transcription Factor JunD Induces Oxidative Stress and Accelerates Age-Related Endothelial Dysfunction. Circulation, 2013, 127, 1229-1240.	1.6	90
140	Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. European Heart Journal, 2013, 34, 2436-2443.	2.2	870
141	SIRT1, p66Shc, and Set7/9 in Vascular Hyperglycemic Memory. Diabetes, 2013, 62, 1800-1807.	0.6	96
142	Deletion of the ageing gene p66Shc reduces early stroke size following ischaemia/reperfusion brain injury. European Heart Journal, 2013, 34, 96-103.	2.2	72
143	Gene Silencing of the Mitochondrial Adaptor p66 ^{Shc} Suppresses Vascular Hyperglycemic Memory in Diabetes. Circulation Research, 2012, 111, 278-289.	4.5	219
144	Assessment of flow-mediated dilation reproducibility. Journal of Hypertension, 2012, 30, 1399-1405.	0.5	125

#	ARTICLE	IF	CITATIONS
145	Expression of the aging gene p66Shc is increased in peripheral blood monocytes of patients with acute coronary syndrome but not with stable coronary artery disease. <i>Atherosclerosis</i> , 2012, 220, 282-286.	0.8	50
146	The clinical relevance of dysfunctional HDL in patients with coronary artery disease: A 3-year follow-up study. <i>International Journal of Cardiology</i> , 2012, 158, 158-160.	1.7	7
147	p66 Shc as the Engine of Vascular Aging. <i>Current Vascular Pharmacology</i> , 2012, 10, 697-699.	1.7	21
148	Prevalence of "Borderline" Values of Cardiovascular Risk Factors in the Clinical Practice of General Medicine in Italy. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2011, 18, 43-51.	2.2	3
149	Oxidized Low-Density Lipoprotein Activates p66 ^{Shc} via Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1, Protein Kinase C- β , and c-Jun N-Terminal Kinase Kinase in Human Endothelial Cells. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2011, 31, 2090-2097.	2.4	87
150	Anti-Aging Medicine: Molecular Basis for Endothelial Cell-Targeted Strategies " A Mini-Review. <i>Gerontology</i> , 2011, 57, 101-108.	2.8	30
151	Is there any memory effect of blood pressure lowering in diabetes?. <i>International Journal of Cardiology</i> , 2011, 151, 384-385.	1.7	3
152	ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries * The Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2011, 32, 2851-2906.	2.2	1,394
153	Is early stage endometrial cancer safely treated by laparoscopy? Complications of a multicenter study and review of recent literature. <i>Surgical Oncology</i> , 2011, 20, 80-87.	1.6	31
154	Antihypertensive Therapy in Diabetes: The Legacy Effect and RAAS Blockade. <i>Current Hypertension Reports</i> , 2011, 13, 318-324.	3.5	31
155	Methods for evaluating endothelial function: a position statement from the European Society of Cardiology Working Group on Peripheral Circulation. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2011, 18, 775-789.	2.8	245
156	Alzheimer's disease and endothelial dysfunction. <i>Neurological Sciences</i> , 2010, 31, 1-8.	1.9	43
157	The Role of Oxidative Stress in Endothelial Dysfunction and Vascular Inflammation. , 2010, , 705-754.		13
158	Dysglycaemia, cardiovascular outcome and treatment. Is the jury still out?. <i>European Heart Journal</i> , 2009, 30, 1301-1304.	2.2	4
159	Impact of Fasting Glycemia and Regional Cerebral Perfusion in Diabetic Subjects. <i>Stroke</i> , 2009, 40, 306-308.	2.0	25
160	Total laparoscopic hysterectomy versus abdominal hysterectomy with lymphadenectomy for early-stage endometrial cancer: A prospective randomized study. <i>Gynecologic Oncology</i> , 2009, 112, 126-133.	1.4	167
161	p66Shc protein, oxidative stress, and cardiovascular complications of diabetes: the missing link. <i>Journal of Molecular Medicine</i> , 2009, 87, 885-891.	3.9	49
162	Final Common Molecular Pathways of Aging and Cardiovascular Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2008, 28, 622-628.	2.4	155

#	ARTICLE	IF	CITATIONS
163	Pulsatile Stretch Induces Release of Angiotensin II and Oxidative Stress in Human Endothelial Cells: Effects of ACE Inhibition and AT ₁ Receptor Antagonism. <i>Clinical and Experimental Hypertension</i> , 2008, 30, 616-627.	1.3	27
164	Vascular Senescence at the Crossroad between Oxidative Stress and Nitric Oxide Pathways. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2008, 15, 17-22.	2.2	1
165	Inhibition of Protein Kinase C β Prevents Foam Cell Formation by Reducing Scavenger Receptor A Expression in Human Macrophages. <i>Circulation</i> , 2008, 118, 2174-2182.	1.6	41
166	c-Jun N-Terminal Kinase 2 Deficiency Protects Against Hypercholesterolemia-Induced Endothelial Dysfunction and Oxidative Stress. <i>Circulation</i> , 2008, 118, 2073-2080.	1.6	83
167	The role of p66Shc deletion in age-associated arterial dysfunction and disease states. <i>Journal of Applied Physiology</i> , 2008, 105, 1628-1631.	2.5	49
168	Genetic deletion of p66 ^{Shc} adaptor protein prevents hyperglycemia-induced endothelial dysfunction and oxidative stress. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 5217-5222.	7.1	229
169	Restoring the Dysfunctional Endothelium. <i>Current Pharmaceutical Design</i> , 2007, 13, 1053-1068.	1.9	35
170	Diabetes and Endothelial Dysfunction. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2007, 14, 5-10.	2.2	3
171	Effects of Olmesartan on Endothelial Function. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2007, 14, 221-227.	2.2	2
172	The Role of eNOS in Vascular Diseases. , 2007, , 227-243.		1
173	Aging and endothelial dysfunction. <i>Clinical Hemorheology and Microcirculation</i> , 2007, 37, 143-7.	1.7	10
174	Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). <i>European Heart Journal</i> , 2006, 28, 88-136.	2.2	1,144
175	Nitric Oxide Release Is Impaired in Hypertensive Individuals With Familial History of Stroke. <i>American Journal of Hypertension</i> , 2006, 19, 1213-1216.	2.0	6
176	Statins Blunt Thrombin-induced Down-regulation of Endothelial Nitric Oxide Synthase Expression in Human Endothelial Cells. <i>Journal of Cardiovascular Pharmacology</i> , 2006, 47, 663-667.	1.9	4
177	Antioxidants and Endothelial Function: Human Studies. <i>Developments in Cardiovascular Medicine</i> , 2006, , 279-304.	0.1	0
178	Viewpoint: Climbing the academic ladder in Italy. <i>Circulation</i> , 2006, 114, f193-4.	1.6	1
179	Hypertension, stroke, and endothelium. <i>Current Hypertension Reports</i> , 2005, 7, 68-71.	3.5	29
180	Glycogen Synthase Kinase-3 Mediates Endothelial Cell Activation by Tumor Necrosis Factor- α . <i>Circulation</i> , 2005, 112, 1316-1322.	1.6	52

#	ARTICLE	IF	CITATIONS
181	The Renin-Angiotensin System, Capri 2005. High Blood Pressure and Cardiovascular Prevention, 2005, 12, 91-108.	2.2	0
182	Angiotensin II type 2 receptors contribute to vascular responses in spontaneously hypertensive rats treated with angiotensin II type 1 receptor antagonists. American Journal of Hypertension, 2005, 18, 493-499.	2.0	107
183	Deletion of p66 ^{shc} Gene Protects Against Age-Related Endothelial Dysfunction. Circulation, 2004, 110, 2889-2895.	1.6	276
184	Selective Inhibition of Protein Kinase C β 2 Prevents Acute Effects of High Glucose on Vascular Cell Adhesion Molecule-1 Expression in Human Endothelial Cells. Circulation, 2004, 110, 91-96.	1.6	120
185	Diabetes and Inflammation. Herz, 2004, 29, 749-759.	1.1	25
186	Protocol for an Observational Blood Pressure Study. High Blood Pressure and Cardiovascular Prevention, 2004, 11, 11-14.	2.2	3
187	Evolving Pathophysiological Perspectives in Endothelial Dysfunction. High Blood Pressure and Cardiovascular Prevention, 2004, 11, 47-53.	2.2	0
188	Pharmacological Mechanisms of Clinically Favorable Properties of a Selective β 1-Adrenoceptor Antagonist, Nebivolol. Cardiovascular Drug Reviews, 2004, 22, 155-168.	4.1	50
189	Diabetes and Vascular Disease. Circulation, 2003, 108, 1527-1532.	1.6	1,249
190	Diabetes and Vascular Disease. Circulation, 2003, 108, 1655-1661.	1.6	397
191	Oxidative Stress and Cardiovascular Disease. High Blood Pressure and Cardiovascular Prevention, 2003, 10, 27-33.	2.2	0
192	Long-Term Tolerability and Efficacy of the Fixed Combination of Manidipine and Delapril in Patients with Essential Hypertension. High Blood Pressure and Cardiovascular Prevention, 2003, 10, 81-86.	2.2	7
193	High Glucose Causes Upregulation of Cyclooxygenase-2 and Alters Prostanoid Profile in Human Endothelial Cells. Circulation, 2003, 107, 1017-1023.	1.6	389
194	Do COX-2 inhibitors really prevent hypertension and proteinuria? Another brick in the wall for the COX-2 inhibition and cardiovascular disease controversy. Journal of Hypertension, 2003, 21, 501-503.	0.5	1
195	Antihypertensive effect and end-organ protection of flavonoids: some insights, more questions. Journal of Hypertension, 2002, 20, 1721-1724.	0.5	2
196	Statin Prevents Tissue Factor Expression in Human Endothelial Cells. Circulation, 2002, 105, 1756-1759.	1.6	320
197	Nitric-oxide-mediated relaxations in salt-induced hypertension: effect of chronic β 1-selective receptor blockade. Journal of Hypertension, 2002, 20, 421-428.	0.5	51
198	AT2-mediated vasorelaxation by angiotensin II in SHR chronically treated with losartan. American Journal of Hypertension, 2002, 15, A13.	2.0	1

#	ARTICLE	IF	CITATIONS
199	Endothelial Dysfunction and Stroke. <i>Journal of Cardiovascular Pharmacology</i> , 2001, 38, S75-S78.	1.9	59
200	Vascular Effects of Newer Cardiovascular Drugs: Focus on Nebivolol and ACE-Inhibitors. <i>Journal of Cardiovascular Pharmacology</i> , 2001, 38, S3-S12.	1.9	16
201	Effects of blood pressure and glucose on endothelial function. <i>Current Hypertension Reports</i> , 2001, 3, 79-88.	3.5	31
202	Reactive Oxygen Species Mediate Endothelium-Dependent Relaxations in Tetrahydrobiopterin-Deficient Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2001, 21, 496-502.	2.4	158
203	Nifedipine inhibits superoxide production induced by pulsatile stretch in human aortic endothelial cells. <i>American Journal of Hypertension</i> , 2000, 13, S34.	2.0	1
204	Abnormalities of Endothelial Function in the Pathogenesis of Stroke: The Importance of Endothelin. <i>Journal of Cardiovascular Pharmacology</i> , 2000, 35, S45-S48.	1.9	36
205	Tetrahydrobiopterin Improves Endothelial Function in Patients with Coronary Artery Disease. <i>Journal of Cardiovascular Pharmacology</i> , 2000, 35, 173-178.	1.9	201
206	Nebivolol Induces NO-Mediated Relaxations of Rat Small Mesenteric But Not of Large Elastic Arteries. <i>Journal of Cardiovascular Pharmacology</i> , 2000, 36, 316-320.	1.9	39
207	Tetrahydrobiopterin and endothelial nitric oxide synthase activity. <i>Cardiovascular Research</i> , 1999, 43, 274-278.	3.8	152
208	Atherosclerosis and the Two Faces of Endothelial Nitric Oxide Synthase. <i>Circulation</i> , 1998, 97, 108-112.	1.6	274
209	Impaired vasorelaxant responses to natriuretic peptides in the stroke-prone phenotype of spontaneously hypertensive rats. <i>Journal of Hypertension</i> , 1998, 16, 151-156.	0.5	12
210	High Glucose Increases Nitric Oxide Synthase Expression and Superoxide Anion Generation in Human Aortic Endothelial Cells. <i>Circulation</i> , 1997, 96, 25-28.	1.6	624
211	Anatomic Heterogeneity of Vascular Aging. <i>Hypertension</i> , 1997, 30, 817-824.	2.7	178
212	Nitric Oxide and Endothelial Regulation of Vascular Tone. <i>Methods in Neurosciences</i> , 1996, , 215-227.	0.5	5
213	Tetrahydrobiopterin and Dysfunction of Endothelial Nitric Oxide Synthase in Coronary Arteries. <i>Circulation</i> , 1995, 91, 139-144.	1.6	243
214	HN-10200 causes endothelium-independent relaxations in isolated canine arteries. <i>Cardiovascular Drugs and Therapy</i> , 1992, 6, 159-165.	2.6	3